5th Jan 2007 07:53
Hutchison China Meditech Limited05 January 2007 5 January 2007 Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Appointment of Joint Broker London: Friday, 5 January 2007: Chi-Med today announces that it has appointedInvestec Bank (UK) Limited as its Joint Broker effective on 5 January 2007.Panmure Gordon (Broking) Limited will continue to act as a broker to Chi-Med. Ends Enquiries Chi-Med Telephone: +852 2121 8200Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571Anthony Carlisle +44 (0) 7973 611 888Chris Gardner +44 (0) 7903 737 649Yvonne Alexander +44 (0) 7866 610 682 Notes to Editors Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and was admitted to trading on the Alternative InvestmentMarket of the London Stock Exchange in May 2006. Chi-Med is focused onresearching, developing, manufacturing, and selling pharmaceuticals, healthsupplements and other consumer health and personal care products derived fromTraditional Chinese Medicine and botanical ingredients. Its overall aim is todraw on the untapped wealth of knowledge and history of usage in the TraditionalChinese Medicine industry to develop products for the global market. The Companyhas three complementary businesses: drug R&D, China healthcare and consumerproducts. Hutchison MediPharma is Chi-Med's wholly-owned drug research and developmentcompany and has a team of around 100 scientists and staff focusing on botanicaldrugs, semi-synthetic natural product drugs, and synthetic single chemicalentity drugs. It currently has two candidates in clinical development in boththe US and China. HMPL-002, a radiosensitiser for head and neck and non-smallcell lung cancer ("NSCLC"), is in Phase I/II in the US and in proof of conceptin China. HMPL-004, an inhibitor to a group of inflammatory cytokines, fortreatment of inflammatory bowel diseases ("IBD"), including Crohn's Disease("CD") and Ulcerative Colitis ("UC"), is in Phase II in the US and in proof ofconcept in China. Hutchison MediPharma also has a pipeline of single molecularentity discovery projects in the auto-immune/inflammatory diseases and oncologytherapeutic areas which have shown activity against clinically validatedtargets. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limted. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hutchmed